Onconova Therapeutics, Inc. (ONTX)

$1.295

-0.03 (-1.89%)
Rating:
Recommendation:
Buy
Symbol ONTX
Price $1.295
Beta 1.822
Volume Avg. 0.10M
Market Cap 27.060M
Shares () -
52 Week Range 1.0-6.77
1y Target Est -
DCF Unlevered ONTX DCF ->
DCF Levered ONTX LDCF ->
ROE -36.41% Strong Sell
ROA -30.28% Strong Sell
Operating Margin -
Debt / Equity 21.60% Neutral
P/E -
P/B 0.64 Buy
Annual
Quarter

Earnings

Consensus EPS

Upgrades & Downgrades

Latest ONTX news


Dr. Steven Fruchtman
Healthcare
Biotechnology
NASDAQ Capital Market

Onconova Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing novel products to treat cancer. It has two clinical-stage programs, including narazaciclib (ON 123300), a multi-targeted kinase inhibitor that is in Phase I study for solid tumors, as well as hematological malignancies as a single agent or in combination with other anti-cancer therapies; and oral rigosertib alone or in combination with PD-1 inhibitor, which is in Phase I/IIa for the treatment of progressive K-Ras mutated non-small cell lung cancer. The company develops a Phase Ib/II ISS with rigosertib monotherapy in patients with advanced squamous cell carcinoma associated with recessive dystrophic epidermolysis bullosa; and has a preclinical program comprising IV/oral rigosertib for COVID-19. It has a license agreement with SymBio Pharmaceuticals Limited; license, development, and commercialization agreement with Pint International SA.; and a license and collaboration agreement with HanX Biopharmaceuticals, Inc. for the development, registration, and commercialization of narazaciclib. Onconova Therapeutics, Inc. was incorporated in 1998 and is headquartered in Newtown, Pennsylvania.